Key result
GFT505 reduced fasting glycaemia and HbA1c and improved insulin sensitivity without inducing the cardiac side-effects associated with PPARγ activation in animal models.
Why the study?
Does GFT505 improve glycemic control without adverse cardiac effects in diabetic animal models compared to PPARγ agonists?
Population
db/db mouse model of diabetes and cynomolgus monkeys
Comparison
GFT505 administered for up to 8 weeks in mice… vs Vehicle, rosiglitazone, or aleglitazar
Design
Preclinical
Follow-up
up to 8 weeks (mice), 12 months (monkeys)
Authors
Loading...
May support clinical testing of GFT505 in diabetes; leaves open translation of cardiac safety to humans.
Does GFT505 improve glycemic control without adverse cardiac effects in diabetic animal models compared to PPARγ agonists?
GFT505 provides anti-diabetic efficacy similar to PPARγ agonists without the associated adverse cardiac effects in preclinical models.
Hanf et al. (2014) studied diabetes. GFT505 vs. vehicle, rosiglitazone, or aleglitazar was evaluated on fasting glycaemia, HbA1c, insulin sensitivity, and cardiac effects. GFT505 reduced fasting glycaemia and HbA1c and improved insulin sensitivity without inducing the cardiac side-effects associated with PPARγ activation in animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: